Do you happen to know if iniury treatment was a recent acquisition, by any chance?
I am fascinated to see how the new contract transpires. I can’t fathom how it will be economically sustainable for the new providers, given the estimated low ball offer + inherent risks dealing with the ADF.
I would very much appreciate any insights you may have here
KKT Price at posting:
15.5¢ Sentiment: Buy Disclosure: Held